Ketamine and Midazolam Infusions for CRPS: Feasibility Study
Complex Regional Pain Syndromes
About this trial
This is an interventional treatment trial for Complex Regional Pain Syndromes focused on measuring Feasibility Study, Ketamine, Midazolam, Complex Regional Pain Syndrome, Active Placebo, Analgesics, Dissociative Anesthetics, Chronic Pain, Neuropathic Pain
Eligibility Criteria
Age 18 to 65 years Meets the International Association for the Study of Pain (IASP) diagnostic criteria for complex regional pain syndrome (CRPS) Primary complaint of CRPS-attributable pain for ≥3 months Average pain intensity of ≥3/10 over the last month Can read and comprehend English-language questionnaires Can receive text messages by phone Can identify a responsible adult who can provide transportation to and from infusion site for 5 consecutive days (Mon-Fri)
Sites / Locations
- Stanford University
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Ketamine and Midazolam
Midazolam and Saline
Participants will receive intravenous infusions of ketamine and midazolam for 4 hours each day, over 5 consecutive days, in an outpatient setting.
Participants will receive intravenous infusions of midazolam and normal saline for 4 hours each day, over 5 consecutive days, in an outpatient setting.